The Cowen and Company Reaffirms “Buy” Rating for Alimera Sciences Inc (ALIM)

The Cowen and Company Reaffirms “Buy” Rating for Alimera Sciences Inc (ALIM)

The analysts wrote, “Alimera has amended its agreement with pSivida to expand Iluvien’s indication in.””

Alimera Sciences Inc (NASDAQ:ALIM)‘s stock had its “buy” rating restated by analysts at Cowen and Company in a note issued to investors on Tuesday, July 11th. They presently have a $3.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s target price suggests a potential upside of 96.08% from the stock’s previous close.

Several other analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Monday, July 10th. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 11th. Finally, Rodman & Renshaw started coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They set a “buy” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) traded down 1.92% during midday trading on Tuesday, reaching $1.53. The company’s stock had a trading volume of 259,605 shares. The stock’s market capitalization is $99.30 million. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.87. The company has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.39.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.20 million. During the same period last year, the business earned ($0.17) earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities research analysts expect that Alimera Sciences will post ($0.21) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALIM. KCG Holdings Inc. raised its position in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 43,977 shares during the period. JW Asset Management LLC raised its position in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 130,000 shares during the period. Finally, Kennedy Capital Management Inc. purchased a new position in shares of Alimera Sciences during the first quarter worth about $467,000. Institutional investors own 43.58% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Related posts

Leave a Comment